• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ARDX

    Ardelyx Inc.

    Subscribe to $ARDX
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: ardelyx.com

    Peers

    $AKBA
    $TCDA
    $ZSAN
    $KDNY

    Recent Analyst Ratings for Ardelyx Inc.

    DatePrice TargetRatingAnalyst
    5/2/2025$11.00Strong Buy → Outperform
    Raymond James
    3/7/2025Buy
    Ladenburg Thalmann
    3/4/2025$14.00Buy
    BTIG Research
    11/11/2024$11.00 → $5.50Buy → Neutral
    H.C. Wainwright
    7/2/2024$15.00 → $7.00Overweight → Neutral
    Piper Sandler
    4/5/2024$14.00Outperform
    Leerink Partners
    12/18/2023$12.00Strong Buy
    Raymond James
    9/7/2023$9.00Buy
    H.C. Wainwright
    8/25/2023$5.00 → $10.00Neutral → Overweight
    Cantor Fitzgerald
    3/3/2023$3.00 → $6.00Neutral → Outperform
    Wedbush
    See more ratings

    Ardelyx Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mott David M bought $1,610,936 worth of shares (381,377 units at $4.22), increasing direct ownership by 19% to 2,396,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:22:23 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Raab Michael sold $177,168 worth of shares (41,666 units at $4.25) and exercised 20,833 shares at a strike of $0.99, decreasing direct ownership by 1% to 1,594,754 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:14:10 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Raab Michael exercised 20,833 shares at a strike of $0.99 and sold $191,151 worth of shares (41,666 units at $4.59), decreasing direct ownership by 1% to 1,615,587 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      4/8/25 7:24:24 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Raab Michael exercised 20,834 shares at a strike of $0.99 and sold $223,199 worth of shares (41,668 units at $5.36), decreasing direct ownership by 1% to 1,635,138 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      3/7/25 7:25:22 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Williams Laura A was granted 105,200 shares, increasing direct ownership by 35% to 409,004 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      2/27/25 6:06:19 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Renz Justin A was granted 136,680 shares, increasing direct ownership by 48% to 422,648 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      2/27/25 6:01:08 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Raab Michael was granted 570,217 shares, increasing direct ownership by 53% to 1,655,972 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      2/27/25 6:00:27 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Kelliher Mike was granted 136,680 shares, increasing direct ownership by 85% to 296,680 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      2/27/25 5:57:56 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Grammer Elizabeth A was granted 136,680 shares, increasing direct ownership by 75% to 317,723 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      2/27/25 5:56:37 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Foster Eric Duane was granted 136,680 shares, increasing direct ownership by 76% to 316,680 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      2/27/25 5:54:50 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ardelyx Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mott David M bought $1,610,936 worth of shares (381,377 units at $4.22), increasing direct ownership by 19% to 2,396,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:22:23 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $388,738 worth of shares (77,729 units at $5.00), increasing direct ownership by 4% to 2,015,494 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      2/26/25 7:21:25 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $992,672 worth of shares (199,000 units at $4.99), increasing direct ownership by 11% to 1,937,765 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      1/22/25 5:25:52 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $996,580 worth of shares (213,300 units at $4.67), increasing direct ownership by 15% to 1,638,765 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      12/23/24 5:59:18 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $996,598 worth of shares (215,868 units at $4.62), increasing direct ownership by 18% to 1,425,465 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      11/14/24 4:26:52 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ardelyx Inc. Leadership Updates

    Live Leadership Updates

    See more

    Ardelyx Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company's board of directors. "We are thrilled to welcome Merdad to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical d

      4/29/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

      WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te

      8/8/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

      WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to Ardelyx an extensive array of mergers and acquisitions, business development, strategy, finance and operational leadership expertise from leading biotechnology and global pharmaceutical companies.

      3/25/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

      CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. "We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are very fortunate to benef

      5/2/22 4:01:00 PM ET
      $ARDX
      $CYTK
      $NTLA
      $VCYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Medical Specialities
    • Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors

      FREMONT, Calif. and WALTHAM, Mass., March 15, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced the appointment of Muna Bhanji, R.Ph, to the company's board of directors, effective March 11, 2021. Ardelyx also announced that long time director, Gordon Ringold, Ph.D., stepped down from the board effective March 11, 2021.   "We are thrilled to welcome Muna to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "She is a veteran leader recognized for developing global strategies in drug

      3/15/21 9:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      11/14/24 4:08:33 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      7/10/24 6:32:11 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      2/13/24 5:26:59 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ardelyx Inc.

      SC 13G - ARDELYX, INC. (0001437402) (Subject)

      2/13/24 4:58:53 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      1/31/24 4:25:59 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      1/30/24 11:37:04 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ardelyx Inc.

      SC 13G - ARDELYX, INC. (0001437402) (Subject)

      1/26/24 4:23:53 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ardelyx Inc.

      SC 13G - ARDELYX, INC. (0001437402) (Subject)

      7/10/23 2:36:44 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      2/14/23 8:25:43 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ardelyx Inc.

      SC 13G - ARDELYX, INC. (0001437402) (Subject)

      2/7/23 4:39:54 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ardelyx Inc. Financials

    Live finance-specific insights

    See more
    • Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

      Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Ardelyx deliver

      5/1/25 4:01:51 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

      WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Inves

      4/17/25 8:00:56 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion Company ended FY 2024 with $250.1 million in cash, cash equivalents and investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended

      2/20/25 7:30:54 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

      WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be avail

      1/30/25 4:30:00 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

      IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH generates $51.5 million in net product sales revenue Company ends Q3 with approximately $190 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2024 and prov

      10/31/24 4:02:40 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024

      WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 31, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the third quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the I

      10/17/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update

      IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2 with approximately $186 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2024 and provided a business update. "In the second quarter, Ardelyx demonstrated our commitment to our mission and to

      8/1/24 4:01:02 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024

      WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, August 1, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2024. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the In

      7/18/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA

      Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in an effort to preserve patient access to its phosphate absorption inhibitor XPHOZAH® (tenapanor), the Company has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services (CMS) En

      7/2/24 7:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update

      Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately $203 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2024 and provided a business update. "The first quarter of 2024 mar

      5/2/24 4:02:28 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ardelyx Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ardelyx downgraded by Raymond James with a new price target

      Raymond James downgraded Ardelyx from Strong Buy to Outperform and set a new price target of $11.00

      5/2/25 8:06:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on Ardelyx

      Ladenburg Thalmann resumed coverage of Ardelyx with a rating of Buy

      3/7/25 8:02:22 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Ardelyx with a new price target

      BTIG Research initiated coverage of Ardelyx with a rating of Buy and set a new price target of $14.00

      3/4/25 7:19:29 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Ardelyx from Buy to Neutral and set a new price target of $5.50 from $11.00 previously

      11/11/24 7:30:39 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Ardelyx from Overweight to Neutral and set a new price target of $7.00 from $15.00 previously

      7/2/24 2:08:43 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Ardelyx with a new price target

      Leerink Partners initiated coverage of Ardelyx with a rating of Outperform and set a new price target of $14.00

      4/5/24 7:23:07 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Ardelyx with a new price target

      Raymond James initiated coverage of Ardelyx with a rating of Strong Buy and set a new price target of $12.00

      12/18/23 8:05:52 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Ardelyx with a new price target

      H.C. Wainwright initiated coverage of Ardelyx with a rating of Buy and set a new price target of $9.00

      9/7/23 8:09:43 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx upgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald upgraded Ardelyx from Neutral to Overweight and set a new price target of $10.00 from $5.00 previously

      8/25/23 7:16:33 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx upgraded by Wedbush with a new price target

      Wedbush upgraded Ardelyx from Neutral to Outperform and set a new price target of $6.00 from $3.00 previously

      3/3/23 8:59:18 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ardelyx Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XPHOZAH issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      10/20/23 4:37:52 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for XPHOZAH issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

      10/18/23 4:43:04 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for XPHOZA™ issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

      10/18/23 4:37:08 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for IBSRELA issued to ARDELYX INC

      Submission status for ARDELYX INC's drug IBSRELA (SUPPL-4) with active ingredient TENAPANOR HYDROCHLORIDE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 211801, Application Classification: Labeling

      4/6/22 1:47:00 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for IBSRELA issued to ARDELYX INC

      Submission status for ARDELYX INC's drug IBSRELA (SUPPL-3) with active ingredient TENAPANOR HYDROCHLORIDE has changed to 'Approval' on 05/19/2021. Application Category: NDA, Application Number: 211801, Application Classification: Labeling

      5/20/21 5:08:39 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for IBSRELA

      Submission status for ARDELYX INC's drug IBSRELA (SUPPL-2) with active ingredient TENAPANOR HYDROCHLORIDE has changed to 'Approval' on 03/05/2021. Application Category: NDA, Application Number: 211801, Application Classification: Labeling

      3/18/21 5:07:47 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ardelyx Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

      WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data supporting the company's first-in-class retainagogue, IBSRELA® (tenapanor), as well as results from the IBS in America 2024 supplemental survey, at the Digestive Disease Week Conference (DDW), now underway in San Diego. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults. "Ardelyx is committed to continuing to grow

      5/6/25 8:01:45 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

      Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Ardelyx deliver

      5/1/25 4:01:51 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company's board of directors. "We are thrilled to welcome Merdad to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical d

      4/29/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

      WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present data supporting the company's first-in-class retainagogue, IBSRELA® (tenapanor), as well as results from the IBS in America 2024 supplemental survey, at the upcoming Digestive Disease Week Conference (DDW), to be held May 3-6, 2025, in San Diego. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults. Title: Safety and Tole

      4/24/25 8:01:45 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

      WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Inves

      4/17/25 8:00:56 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

      WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), as a poster at the National Kidney Foundation (NKF) Spring Clinical Meetings, now underway in Boston. Ardelyx is also hosting an Exhibitor Showcase discussing hyperphosphatemia management. XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administrati

      4/10/25 4:02:47 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

      WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that an abstract detailing a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), was accepted as a poster presentation at the National Kidney Foundation (NKF) Spring Clinical Meetings, to be held April 10-13, 2025, in Boston. XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults wit

      3/31/25 4:03:51 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

      WALTHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, is proud to announce on World Kidney Day that Mary Baliker, Erich Ditschman, Nichole Jefferson, Curtis Warfield and David M. White are the first recipients of the Derek Forfang Patient Advocate Award. This award was established to honor Derek Forfang, who suffered from chronic kidney disease (CKD) and passed away due to issues related to his disease in 2023. Derek worked tirelessly to improve the lives of patients, families and caregivers in t

      3/13/25 8:02:40 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenapanor Approved in China for Hyperphosphatemia

      WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the approval of a New Drug Application (NDA) by China's Center for Drug Evaluation of the National Medical Products Administration for tenapanor to control serum phosphorus levels in dialysis patients with chronic kidney disease (CKD) who have an inadequate response or are intolerant to phosphorus binders. This approval triggers a $5 million milestone payment to Ardelyx under the terms of the license agreement between Ardelyx an

      2/26/25 7:00:38 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Participate in Upcoming Investor Conferences

      WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2025 Global Healthcare ConferenceLocation: Miami, FLPresentation: Tuesday, March 11 at 8:00 a.m. ET1x1 Meetings: Tuesday, March 11 To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the presentation will be available on the Ardelyx websit

      2/25/25 4:15:00 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ardelyx Inc. SEC Filings

    See more
    • SEC Form 144 filed by Ardelyx Inc.

      144 - ARDELYX, INC. (0001437402) (Subject)

      5/2/25 4:22:02 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ardelyx Inc.

      10-Q - ARDELYX, INC. (0001437402) (Filer)

      5/1/25 4:04:48 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARDELYX, INC. (0001437402) (Filer)

      5/1/25 4:03:36 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Ardelyx Inc.

      DEF 14A - ARDELYX, INC. (0001437402) (Filer)

      4/30/25 7:47:17 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - ARDELYX, INC. (0001437402) (Filer)

      4/29/25 8:02:23 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Ardelyx Inc.

      10-K - ARDELYX, INC. (0001437402) (Filer)

      2/20/25 12:08:28 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARDELYX, INC. (0001437402) (Filer)

      2/20/25 7:34:27 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ardelyx Inc.

      SCHEDULE 13G/A - ARDELYX, INC. (0001437402) (Subject)

      2/14/25 12:57:20 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Ardelyx Inc.

      144 - ARDELYX, INC. (0001437402) (Subject)

      2/12/25 5:58:54 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Ardelyx Inc.

      SCHEDULE 13G - ARDELYX, INC. (0001437402) (Subject)

      2/5/25 7:46:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care